Janus Kinase Inhibitors and Non-Melanoma Skin Cancer

Charlotte S. Greif, Divya Srivastava, Rajiv I. Nijhawan

Research output: Contribution to journalArticlepeer-review

Abstract

JAK (janus kinase) inhibitors are becoming increasingly prescribed for various conditions from dermatologic diseases to graft versus host disease in bone marrow transplant recipients. This class of drugs has been found to be truly life-changing for many, though they are not without potential adverse effects. While JAK inhibitors have not been shown to significantly increase the risk of non-melanoma skin cancer (NMSC) in large scale clinical trials, NMSC is one of the most concerning possible adverse events, and there have been several reported cases of aggressive squamous cell carcinomas, especially in our already immunosuppressed patient populations. In these patients, it is incredibly important that patients are on the lowest possible dosage of the JAK inhibitor. In addition, these patients must be routinely screened by a dermatologist with a comprehensive skin exam to ensure early detection if skin cancer was to develop. For those patients diagnosed with skin cancer, early intervention is key to optimize outcomes, and at times, multi-disciplinary care coordination is needed. In the future, large-scale studies with longer follow-up of patients would help determine whether JAK inhibitors significantly increase the risk of NMSC.

Original languageEnglish (US)
Article number11
JournalCurrent treatment options in oncology
Volume22
Issue number2
DOIs
StatePublished - Feb 2021

Keywords

  • Immunomodulation
  • JAK inhibitor
  • Janus kinase inhibitor
  • Mohs surgery
  • Non-melanoma skin cancer
  • Ruxolitinib
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Janus Kinase Inhibitors and Non-Melanoma Skin Cancer'. Together they form a unique fingerprint.

Cite this